A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum.
Ontology highlight
ABSTRACT: Potent and durable vaccine responses will be required for control of malaria caused by Plasmodium falciparum (Pf). RTS,S/AS01 is the first, and to date, the only vaccine that has demonstrated significant reduction of clinical and severe malaria in endemic cohorts in Phase 3 trials. Although the vaccine is protective, efficacy declines over time with kinetics paralleling the decline in antibody responses to the Pf circumsporozoite protein (PfCSP). Although most attention has focused on antibodies to repeat motifs on PfCSP, antibodies to other regions may play a role in protection. Here, we expressed and characterized seven monoclonal antibodies to the C-terminal domain of CSP (ctCSP) from volunteers immunized with RTS,S/AS01. Competition and crystal structure studies indicated that the anti
SUBMITTER: Beutler N
PROVIDER: S-EPMC8989322 | biostudies-literature | 2022 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA